## Theresa L Wampler Muskardin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3258690/publications.pdf

Version: 2024-02-01

839539 840776 19 926 11 18 g-index citations h-index papers 21 21 21 1970 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19. Translational Research, 2022, 244, 47-55.	5.0	9
2	A fatal case of malignant atrophic papulosis in a pediatric patient. Pediatric Dermatology, 2022, 39, 112-114.	0.9	3
3	Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Annals of the Rheumatic Diseases, 2021, 80, 550-557.	0.9	109
4	Novel mutation in the NRLP3 manifesting as an intermediate phenotype of cryopyrinopathies. Rheumatology International, 2021, 41, 219-225.	3.0	4
5	Distinct Single Cell Gene Expression in Peripheral Blood Monocytes Correlates With Tumor Necrosis Factor Inhibitor Treatment Response Groups Defined by Type I Interferon in Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 1384.	4.8	12
6	Lessons from precision medicine in rheumatology. Multiple Sclerosis Journal, 2020, 26, 533-539.	3.0	11
7	Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019. ACR Open Rheumatology, 2020, 2, 283-285.	2.1	33
8	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. Journal of Clinical Investigation, 2020, 130, 1669-1682.	8.2	142
9	Interferon Chemokine Score and Other Cytokine Measures Track With Changes in Disease Activity in Patients With Juvenile and Adult Dermatomyositis. ACR Open Rheumatology, 2019, 1, 83-89.	2.1	10
10	Type I interferon in rheumatic diseases. Nature Reviews Rheumatology, 2018, 14, 214-228.	8.0	226
11	Brief Report: A Novel <i>ELANE</i> Mutation Associated With Inflammatory Arthritis, Defective NETosis, and Recurrent Parvovirus Infection. Arthritis and Rheumatology, 2017, 69, 2396-2401.	5.6	17
12	Population-based study of outcomes of patients with juvenile idiopathic arthritis (JIA) compared to non-JIA subjects. Seminars in Arthritis and Rheumatism, 2017, 46, 439-443.	3.4	14
13	Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation. Arthritis Research and Therapy, 2017, 19, 212.	3.5	35
14	Febrile infectionâ€related epilepsy syndrome treated with anakinra. Annals of Neurology, 2016, 80, 939-945.	5.3	208
15	Juvenile Idiopathic Arthritis in Olmsted County, Minnesota, 1960–2013. Arthritis and Rheumatology, 2016, 68, 247-254.	5.6	25
16	Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort. Clinical Rheumatology, 2016, 35, 1493-1499.	2.2	5
17	Increased pretreatment serum IFN- $\hat{l}^2/\hat{l}^{\pm}$ ratio predicts non-response to tumour necrosis factor $\hat{l}^{\pm}$ inhibition in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1757-1762.	0.9	59
18	A 45â€yearâ€old man with flank pain and inability to ejaculate. Arthritis Care and Research, 2012, 64, 616-622.	3.4	0

## THERESA L WAMPLER

#	Article	IF	CITATIONS
19	Malar Rash in Systemic Juvenile Idiopathic Arthritis: Figure 1 Journal of Rheumatology, 2010, 37, 2187-2187.	2.0	3